Pier 88 Investment Partners’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Pier 88 Investment Partners’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-20,515	Closed	-$712K	–	105
2019 Q1	$712K	Buy	20,515 +12,715	+163%	+$367K	0.33%	59
2018 Q4	$152K	Sell	7,800 -7,660	-50%	-$158K	0.08%	83
2018 Q3	$412K	Buy	15,460 +4,025	+35%	+$131K	0.18%	70
2018 Q2	$432K	Buy	+11,435	New	+$437K	0.2%	66

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Pier 88 Investment Partners's PTLA Position: Q2 2019 in Review

Pier 88 Investment Partners sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 20,515 shares — an estimated $712K sold.

Pier 88 Investment Partners first reported a position in PTLA in Q2 2018 and held it in 4 quarters. The position peaked at $712K in Q1 2019. 202 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

Pier 88 Investment Partners reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Pier 88 Investment Partners sold 20,515 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $712K.
Pier 88 Investment Partners first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 4 quarters.
Pier 88 Investment Partners's Portola Pharmaceuticals, Inc. position peaked at $712K in Q1 2019.
202 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on Pier 88 Investment Partners's 13F filing for Q2 2019, filed 8 Aug 2019.